Moller, David E.

Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action

Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation

Metabolism, Diabetes, and CancerPeroxisome Proliferator-Activated Receptors

Cited by 5,652

The mechanisms of action of PPARs

Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 2,659

Fibroblast Growth Factor 21 Corrects Obesity in Mice

Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 1,031

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 885

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., et al. (2002) · Diabetes

Metabolism, Diabetes, and CancerDiabetes Treatment and Management

Cited by 806

Evidence Against Altered Expression of GLUT1 or GLUT4 in Skeletal Muscle of Patients With Obesity or NIDDM

Pedersen, O., Bak, J. F., Andersen, P. H., Lund, S., Moller, D. E., Flier, J. S., & Kahn, B. B. (1990) · Diabetes

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 329

Activation of PPARδ alters lipid metabolism in db/db mice

Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters

Peroxisome Proliferator-Activated ReceptorsCholesterol and Lipid Metabolism

Cited by 308

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Gimeno, R. E., & Moller, D. E. (2014) · Trends in Endocrinology & Metabolism

Fibroblast Growth Factor ResearchAdipokines, Inflammation, and Metabolic Diseases

Cited by 163

Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)

Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 96

Normal Insulin-Receptor cDNA Sequence in Pima Indians With NIDDM

Moller, D. E., Yokota, A., & Flier, J. S. (1989) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsMetabolism, Diabetes, and Cancer

Cited by 76

Molecular Scanning of Insulin-Responsive Glucose Transporter (GLUT4) Gene in NIDDM Subjects

Choi, W.-H., O'Rahilly, S., Buse, J. B., Rees, A., Morgan, R., Flier, J. S., & Moller, D. E. (1991) · Diabetes

Metabolism, Diabetes, and CancerGenetic Associations and Epidemiology

Cited by 70